News - Health Medical Pharma

Filter

Current filters:

Health Medical Pharma

Popular Filters

1 to 25 of 64 results

BioAlliance’s Sitavig debuts in USA; new patent granted

BioAlliance’s Sitavig debuts in USA; new patent granted

22-07-2014

French drug developer BioAlliance Pharma says that its US partner Innocutis Holdings has launched Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyHealth Medical PharmaHerpesInnocutis HoldingsLabial herpesMarkets & MarketingMedicineMicrobiologyPatentsSitavigUSA

US court preliminary order to prevent Actavis launch of generic Gralise

US court preliminary order to prevent Actavis launch of generic Gralise

18-07-2014

Judge Joel Pisano of the US District Court for the District of New Jersey has entered an order preliminarily…

ActavisActavis Elizabeth LLCAnticonvulsantsDepomedGenericsGraliseHealth Medical PharmaLaw CrimeLegalNeurologicalPatentsPfizerUSA

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

15-07-2014

In an interview with The Pharma Letter, Nicholas Saccomano, chief science officer of Array BioPharma,…

Array BioPharmaBiogen IdecBiotechnologyChief science officerHealth Medical PharmaInterviewsMelanomaOncologyProtein kinase inhibitorUSA

Anthera appoints Chuck Olson as president of Alkira

Anthera appoints Chuck Olson as president of Alkira

15-07-2014

US-based biopharma Anthera Pharmaceuticals has appointed Chuck Olson as president of its subsidiary Alkira…

Anthera PharmaceuticalsBoardroomBusiness FinanceBusiness FinanceGastro-intestinalsHealth Medical PharmaPancreasPharmaceuticalProduct manufacturingUSA

ScinoPharm chief exec Jo Shen to retire and be replaced by Yung-Fa Chen

ScinoPharm chief exec Jo Shen to retire and be replaced by Yung-Fa Chen

11-07-2014

Taiwan-based pharmaceutical company ScinoPharm (TWSE: 1789) says that its president and chief executive…

Asia-PacificBoardroomBusiness FinanceChenHealth Medical PharmaPharmaceuticalPharmaceutical industryPresident and chief executiveScinoPharm

Actavis and Forest to divest four generics to gain FTC OK for merger

01-07-2014

In order for Ireland-headquartered generics major Actavis to complete its previously-announced $25 billion…

ActavisForest LaboratoriesGeneric pharmaceuticalsGenericsHealth Medical PharmaMedicinePharmaceutical industryPharmacologyRegulationUSA

Health spending starts to rise but remains weak in Europe, says OECD

Health spending starts to rise but remains weak in Europe, says OECD

30-06-2014

Health spending has started to rise again after stagnating or even falling in many OECD countries during…

EuropeHealth Medical PharmaHealthcarePharmaceutical

Actavis files for generic version of Acorda’s Ampyra

Actavis files for generic version of Acorda’s Ampyra

27-06-2014

US biotech firm Acorda Therapeutics has been advised that Ireland-headquartered generics major Actavis…

Acorda TherapeuticsActavisAmpyraGenericsHealth Medical PharmaMedicinePharmaceutical sciencesPharmacologyRegulationUS Food and Drug AdministrationUSA

Vertex leaps on positive Ph III results with lumacaftor

Vertex leaps on positive Ph III results with lumacaftor

24-06-2014

US biotech firm Vertex Pharmaceuticals saw its share price rocket nearly 52% to $101.20 in extending…

BiotechnologyBusiness FinanceCystic fibrosisHealth Medical PharmaKalydecolumacaftorMedicinePhenolsRare diseasesRegulationResearchVertex Pharmaceuticals

Novartis subject to Italian investigation over alleged vaccine fraud

Novartis subject to Italian investigation over alleged vaccine fraud

23-06-2014

Swiss drug maker Novartis is the subject of a new investigation by Italian authorities. The company’s…

Health Medical PharmaInfluenzaItalyLegalMedicineNovartisPharmaceuticalPharmacologyVaccines

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen

18-06-2014

US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

16-06-2014

UK pharma major GlaxoSmithKline announced the results from the Phase III PETIT2 study evaluating the…

eltrombopagEuropeGlaxoSmithKlineHealth Medical PharmaHematologyItalyMajorMedicinePharmaceuticalResearchThrombocytopenic purpura

MorphoSys and Merck Serono collaborate on immuno-oncology

MorphoSys and Merck Serono collaborate on immuno-oncology

12-06-2014

German companies MorphoSys and Merck KGaA unit Merck Serono today announced the signing of an agreement…

BiotechnologyCancer therapyHealth Medical PharmaHuman antibody technologiesImmune systemImmunologicalsLeaderLicensingMerck KGaAMerck SeronoMorphoSysOncologyResearch

Lilly’s Cyramza disappoints in Ph III liver cancer trial

Lilly’s Cyramza disappoints in Ph III liver cancer trial

12-06-2014

US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients…

ChemistryCyramzaEli LillyHealth Medical PharmaLillyMajorOncologyOrganic chemistryPharmaceuticalResearch

Orexigen stock falls after FDA extends review of obesity drug

Orexigen stock falls after FDA extends review of obesity drug

11-06-2014

Obesity-focused US biopharmaceutical company Orexigen Therapeutics says that the US Food and Drug Administration…

AnorecticsBiopharmaceuticalCardio-vascularContraveHealth Medical PharmaNB32Orexigen TherapeuticsPharmaceuticalPharmacologyRegulationUSA

Novartis’ Glivec could lose half patient population in China to generics

Novartis’ Glivec could lose half patient population in China to generics

03-06-2014

Hematologists in China estimate that Glivec (imatinib) from Swiss drug major Novartis will lose nearly…

Blast phase CMLChemistryChinaChronic phase CMLGlivecHealth Medical PharmaHematologyMajorMarkets & MarketingNovartisPharmaceutical

1 to 25 of 64 results

Back to top